ScinoPharm Taiwan Past Earnings Performance
Past criteria checks 5/6
ScinoPharm Taiwan has been growing earnings at an average annual rate of 8.3%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 3.3% per year. ScinoPharm Taiwan's return on equity is 3.8%, and it has net margins of 11.4%.
Key information
8.3%
Earnings growth rate
8.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 3.3% |
| Return on equity | 3.8% |
| Net Margin | 11.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year
Jun 17
Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First
Apr 04A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)
Mar 14Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock
Feb 21ScinoPharm Taiwan's (TPE:1789) Shareholders Are Down 45% On Their Shares
Jan 25
We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease
Jan 04Estimating The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)
Dec 14Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?
Nov 23Revenue & Expenses Breakdown
How ScinoPharm Taiwan makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,493 | 399 | 547 | 387 |
| 30 Jun 24 | 3,428 | 403 | 558 | 334 |
| 31 Mar 24 | 3,421 | 385 | 551 | 356 |
| 31 Dec 23 | 3,186 | 287 | 544 | 358 |
| 30 Sep 23 | 3,079 | 231 | 522 | 355 |
| 30 Jun 23 | 3,124 | 261 | 523 | 333 |
| 31 Mar 23 | 3,175 | 318 | 533 | 298 |
| 31 Dec 22 | 3,264 | 353 | 574 | 271 |
| 30 Sep 22 | 2,968 | 305 | 613 | 264 |
| 30 Jun 22 | 2,917 | 254 | 658 | 274 |
| 31 Mar 22 | 2,859 | 230 | 681 | 265 |
| 31 Dec 21 | 2,762 | 243 | 686 | 306 |
| 30 Sep 21 | 2,917 | 198 | 681 | 276 |
| 30 Jun 21 | 3,021 | 266 | 692 | 301 |
| 31 Mar 21 | 3,182 | 337 | 708 | 288 |
| 31 Dec 20 | 3,083 | 282 | 696 | 246 |
| 30 Sep 20 | 3,028 | 323 | 684 | 243 |
| 30 Jun 20 | 2,954 | 279 | 682 | 232 |
| 31 Mar 20 | 2,663 | 174 | 662 | 235 |
| 31 Dec 19 | 2,893 | 217 | 671 | 238 |
| 30 Sep 19 | 2,933 | 262 | 681 | 296 |
| 30 Jun 19 | 3,067 | 312 | 672 | 263 |
| 31 Mar 19 | 3,435 | 386 | 675 | 308 |
| 31 Dec 18 | 3,524 | 443 | 671 | 313 |
| 30 Sep 18 | 3,560 | 410 | 655 | 285 |
| 30 Jun 18 | 3,591 | 434 | 660 | 317 |
| 31 Mar 18 | 3,458 | 388 | 650 | 305 |
| 31 Dec 17 | 3,516 | 422 | 677 | 314 |
| 30 Sep 17 | 3,624 | 508 | 684 | 294 |
| 30 Jun 17 | 3,767 | 567 | 672 | 283 |
| 31 Mar 17 | 3,929 | 657 | 675 | 276 |
| 31 Dec 16 | 4,031 | 659 | 658 | 280 |
| 30 Sep 16 | 4,059 | 707 | 649 | 305 |
| 30 Jun 16 | 4,050 | 736 | 647 | 309 |
| 31 Mar 16 | 3,998 | 694 | 644 | 315 |
| 31 Dec 15 | 3,955 | 635 | 603 | 324 |
| 30 Sep 15 | 3,775 | 445 | 589 | 331 |
| 30 Jun 15 | 3,795 | 371 | 591 | 355 |
| 31 Mar 15 | 3,980 | 432 | 595 | 399 |
| 31 Dec 14 | 4,098 | 484 | 625 | 416 |
| 30 Sep 14 | 4,572 | 744 | 694 | 455 |
| 30 Jun 14 | 4,809 | 875 | 698 | 451 |
| 31 Mar 14 | 5,000 | 1,089 | 712 | 417 |
| 31 Dec 13 | 5,088 | 1,273 | 727 | 418 |
Quality Earnings: 1789 has high quality earnings.
Growing Profit Margin: 1789's current net profit margins (11.4%) are higher than last year (7.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1789's earnings have grown by 8.3% per year over the past 5 years.
Accelerating Growth: 1789's earnings growth over the past year (72.7%) exceeds its 5-year average (8.3% per year).
Earnings vs Industry: 1789 earnings growth over the past year (72.7%) exceeded the Pharmaceuticals industry 11.9%.
Return on Equity
High ROE: 1789's Return on Equity (3.8%) is considered low.